Ergomed Award of Share Options
16/06/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230616:nRSP9186Ca&default-theme=true
RNS Number : 9186C Ergomed plc 16 June 2023
PRESS RELEASE
Ergomed Award of Share Options
Guildford, UK - 16 June 2023: Ergomed plc (LSE: ERGO) ("Ergomed" or the
"Company"), a company focused on providing specialised services to the
pharmaceutical industry, today announces that the following LTIP (Long Term
Incentive Plan) awards were made to Jonathan Curtain (Chief Financial Officer)
on 15 June 2023.
Mr Curtain was awarded a total of 28,866 options over the Company's ordinary
shares. The options have an exercise price of 1 pence per share. Of the
total option award to Mr Curtain, 75% will vest three years after the grant
date, conditional upon the achievement of total shareholder return of 15%
(compounded annual growth rate). The remaining 25% will vest three years after
the grant date subject to continued employment. The option grant comprises
annual discretionary LTIP awards for which Mr Curtain is eligible.
The notification below, made in accordance with the requirements of Article 19
of the UK Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Jonathan Curtain
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial Notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Ergomed plc
b) Legal Entity Identifier 213800BVS8I9VMC1AP84
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options over ordinary shares of 1 pence each
Identification code
GB00BN7ZCY67
b) Nature of the transaction Grant of options under the Company's Long Term Incentive Plan
c) Currency GBP
d) Price(s) and volume(s) Price(s) Volume(s)
1 pence 28,866
e) Aggregated information Options over 28,866 ordinary shares at an exercise price of 1 pence per share
- Aggregated volume
- Price
- Aggregated total
f) Date of the transaction 15 June 2023
g) Place of the transaction Outside a trading venue
ENDS
Enquiries:
Ergomed plc
Tel: +44 (0) 1483 402 975
Dr Miroslav Reljanović (Executive Chairman)
Jonathan Curtain (Chief Financial Officer)
Keith Byrne (Senior Vice-President, Capital Markets and
Strategy)
Numis Securities Limited (Nominated Advisor and Joint
Tel: +44 (0) 20 7260 1000
Broker)
Freddie Barnfield / Euan Brown/ Jack McLaren
Peel Hunt Securities Limited (Joint Broker)
Tel: +44 (0) 20 7418 8900
James Steel / Dr Christopher Golden
Consilium Strategic Communications - for UK enquiries Tel:
+44 (0) 20 3709 5700
Chris Gardner / Matthew Neal
ergomed@consilium-comms.com
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHUVOKROKUNAAR